Meeting
2016 ASCO Annual Meeting
STARVE-PC: Biomarker-driven phase 2 study of ipilimumab plus nivolumab for AR-V7-expressing metastatic castration-resistant prostate cancer (mCRPC).
Authors
Karim Boudadi
Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD
Karim Boudadi , Daniel L. Suzman , Brandon Luber , Hao Wang , John L. Silberstein , Maritza N. Taylor , Rana Sullivan , Donna Dowling , Rana Harb , Ryan Vance Dittamore , Alan Meeker , Jun Luo , Charles G. Drake , Emmanuel S. Antonarakis
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Genitourinary (Prostate) Cancer
Track
Genitourinary Cancer—Prostate, Testicular, and Penile
Sub Track
Prostate Cancer - Advanced Disease
Clinical Trial Registration Number
NCT02601014
Citation
J Clin Oncol 34, 2016 (suppl; abstr TPS5089)
DOI
10.1200/JCO.2016.34.15_suppl.TPS5089
Abstract #
TPS5089
Poster Bd #
438a
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Genitourinary Cancers Symposium
Evolution: Phase II study of radionuclide 177Lu-PSMA-617 therapy versus 177Lu-PSMA-617 in combination with ipilimumab and nivolumab for men with metastatic castration-resistant prostate cancer (mCRPC; ANZUP 2001).
First Author: Shahneen Sandhu
Poster
2024 ASCO Genitourinary Cancers Symposium
A phase 2 study of cabozantinib and nivolumab in metastatic castration-resistant prostate cancer (CANOPY).
First Author: Yu-Wei Chen
Poster
2023 ASCO Genitourinary Cancers Symposium
Nivolumab plus ipilimumab for the treatment of post-chemotherapy metastatic castration-resistant prostate cancer (mCRPC): Additional results from the randomized phase 2 CheckMate 650 trial.
First Author: Padmanee Sharma
Poster
2021 ASCO Annual Meeting
A phase II study evaluating the efficacy of enzalutamide and the role of ARv7 in metastatic castration-resistant prostate cancer (mCRPC) patients (pts) with visceral disease.
First Author: Pierangela Sepe